Novel misoprostol insert reduces labor time, need for oxytocin

Novel misoprostol insert reduces labor time, need for oxytocin
Use of a 200-microgram misoprostol vaginal insert significantly reduces the time to vaginal delivery and the need for oxytocin, in women with an unfavorable cervix, compared to those using a dinoprostone vaginal insert, according to a study published online July 8 in Obstetrics & Gynecology.

(HealthDay)—Use of a 200-microgram misoprostol vaginal insert significantly reduces the time to vaginal delivery and the need for oxytocin, in women with an unfavorable cervix, compared to those using a dinoprostone vaginal insert, according to a study published online July 8 in Obstetrics & Gynecology.

Deborah A. Wing, M.D., from the University of California at Irvine, and colleagues randomly assigned women being induced with a modified Bishop score of 4 or less to receive either a 200- vaginal insert (678 patients) or a 10-mg dinoprostone vaginal insert (680 patients).

The researchers found that women receiving the misoprostol vaginal insert had a significantly shorter median time to compared with patients receiving the dinoprostone vaginal insert (21.5 hours versus 32.8 hours). Twenty-six percent of women receiving the misoprostol vaginal insert and 27.1 percent of those with the dinoprostone vaginal insert had a cesarean delivery. The misoprostol vaginal insert was significantly associated with a reduction in time to any delivery (18.3 versus 27.3 hours), time to onset of active labor (12.1 versus 18.6 hours), and proportion of women requiring predelivery (48.1 versus 74.1 percent), compared with the dinoprostone vaginal insert. Participants experienced uterine tachysystole requiring intervention in 13.3 and 4.0 percent of cases receiving the misoprostol vaginal insert and dinoprostone vaginal insert, respectively.

"Use of a 200-microgram misoprostol vaginal inset significantly reduced times to vaginal delivery and active labor with reduced need for oxytocin compared with the dinoprostone vaginal insert," the authors write.

The authors disclosed financial ties to Ferring Pharmaceuticals, which manufactures the misoprostol vaginal insert and contributed funding to the study.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Vaginal delivery ups risk of pelvic organ prolapse

Jul 02, 2013

(Medical Xpress)—Women who give birth vaginally are at increased risk of developing pelvic organ prolapse during the year after delivery, according to a study of Chinese women by researchers at Yale School ...

Recommended for you

AAFP advocates for planned vaginal birth after cesarean

2 hours ago

(HealthDay)—A planned labor and vaginal birth after cesarean (LAC/VBAC) is an appropriate option for most women with a history of prior cesarean birth, according to a clinical practice guideline published ...

Women diagnosed with PCOS twice as likely to be hospitalized

Jan 27, 2015

Women diagnosed with polycystic ovary syndrome - the most common hormone disorder in women of reproductive age - face a heightened risk of developing heart disease, diabetes, mental health conditions, reproductive disorders ...

Risks for Ebola virus-infected pregnant women discussed

Jan 22, 2015

(HealthDay)—Ebola virus-infected pregnant women are at risk for adverse maternal and fetal outcomes, according to an article published online Jan. 14 in BJOG: An International Journal of Obstetrics & Gy ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.